Heidi Russell

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy
    Heidi Russell
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 53:23-7. 2009
  2. ncbi A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma
    Heidi V Russell
    Department of Pediatrics, Texas Children s Cancer Center, Houston, TX 77030, USA
    J Immunother 31:812-9. 2008
  3. ncbi Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin
    Heidi V Russell
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunother 30:227-33. 2007
  4. ncbi Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 29:316-23. 2011
  5. ncbi CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases
    Heidi V Russell
    Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    J Pediatr Surg 39:1506-11. 2004
  6. ncbi The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma
    Heidi V Russell
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 45:916-9. 2005
  7. ncbi Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients
    Andre N Gay
    Division of Pediatric Surgery, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030 2399, USA
    J Pediatr Surg 43:837-42. 2008
  8. ncbi Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow
    Mehmet Fatih Okcu
    Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Pediatr Blood Cancer 45:787-95. 2005
  9. ncbi Refractory dilated cardiomyopathy associated with metastatic neuroblastoma
    Peter Carlson
    Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 55:736-8. 2010
  10. ncbi Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma
    Rachel A Egler
    Department of Pediatrics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 14:7028-34. 2008

Collaborators

  • Eric Yvon
  • Raphael Rousseau
  • Ettore Biagi
  • Rachel A Egler
  • Mehmet Fatih Okcu
  • H E Heslop
  • A P Gee
  • M J Hicks
  • John Hicks
  • C Rossig
  • Sanjeev A Vasudevan
  • Xiaoying Shang
  • Jianhua Yang
  • Susan M Burlingame
  • Jed G Nuchtern
  • Stacey L Berg
  • Peter Carlson
  • Ningling Ge
  • Shirong Chang
  • Andre N Gay
  • Martin A Pule
  • Ashish Mark Ingle
  • Nianhang Chen
  • Mitchell S Cairo
  • Peter C Adamson
  • Janet Ayello
  • Henry Lau
  • Susan M Blaney
  • Debra Kearney
  • John L Jefferies
  • Jose L Diaz-Miron
  • Rodney D David
  • Catherine L Wesson
  • Eugene S Kim
  • Andrew D Ludwig
  • Xiaoyi Shang
  • Javed Khan
  • Lindsey Rutland
  • Gianpietro Dotti
  • Oluyinka O Olutoye
  • Barbara Savoldo
  • Darrell L Cass
  • G Doug Myers
  • Heidi L Weiss
  • Cliona M Rooney
  • Sarah Byeseda
  • Zhuyong Mei
  • M Helen Huls
  • Enli Liu
  • Hao Liu
  • Bindi Naik-Mathuria
  • Ling Yu
  • Malcolm K Brenner
  • Zhiyun J Liu

Detail Information

Publications14

  1. ncbi Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy
    Heidi Russell
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 53:23-7. 2009
    ..This report describes the histologic changes and outcomes in four patients with IF treated with chemotherapy and surgical resection...
  2. ncbi A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma
    Heidi V Russell
    Department of Pediatrics, Texas Children s Cancer Center, Houston, TX 77030, USA
    J Immunother 31:812-9. 2008
    ..Median event-free survival was 22 months for patients in first remission and 3 months for all others. Four patients treated in first remission remain alive and 3 without disease recurrence...
  3. ncbi Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin
    Heidi V Russell
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Immunother 30:227-33. 2007
    ..In this setting, the immune response was insufficient to overcome active recurrent neuroblastoma...
  4. ncbi Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 29:316-23. 2011
    ....
  5. ncbi CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases
    Heidi V Russell
    Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    J Pediatr Surg 39:1506-11. 2004
    ..The goal of this study was to investigate whether the degree of expression of CXCR4 on cells from neuroblastoma primary tumors was related to the pattern of metastatic involvement...
  6. ncbi The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma
    Heidi V Russell
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 45:916-9. 2005
    ..If stage of disease rarely changed with bone marrow results, it might be possible to avoid this procedure in a subset of patients with neuroblastoma...
  7. ncbi Granulocyte colony stimulating factor alters the phenotype of neuroblastoma cells: implications for disease-free survival of high-risk patients
    Andre N Gay
    Division of Pediatric Surgery, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030 2399, USA
    J Pediatr Surg 43:837-42. 2008
    ..We hypothesized that exogenous GCSF stimulates the proliferation and invasive character of neuroblastoma cells...
  8. ncbi Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow
    Mehmet Fatih Okcu
    Division of Pediatrics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Pediatr Blood Cancer 45:787-95. 2005
    ..5-95%) compared to a CD56-/CD45+ internal control population (2-8%). CONCLUSIONS: Our preliminary results suggest that FCM determination of the percent of CD9+/CD56+/CD45- cells is an effective method of rapidly detecting NB cells in BM...
  9. ncbi Refractory dilated cardiomyopathy associated with metastatic neuroblastoma
    Peter Carlson
    Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 55:736-8. 2010
    ..However, the tumor proved unresponsive to treatment. The patient died from stage IV congestive heart failure (CHF) and progressive NB. Autopsy confirmed dilated cardiomyopathy with endocardial fibroelastosis...
  10. ncbi Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma
    Rachel A Egler
    Department of Pediatrics, Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 14:7028-34. 2008
    ..To explore the relationships between interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) levels and disease extent and clinical outcome in childhood neuroblastoma...
  11. ncbi Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma
    Sanjeev A Vasudevan
    Michael E DeBakey Department of Surgery, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2478-89. 2009
    ..Furthermore, NDSP serves as a growth factor for neuroblastoma tumor cells through activation of the ERK-mediated proliferation pathway...
  12. ncbi Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma
    Xiaoying Shang
    Texas Children s Cancer Center, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2461-9. 2009
    ..Overexpression of Aurora A is associated with disease progression in neuroblastoma. Inhibition of this kinase is a promising modality for neuroblastoma treatment...
  13. ncbi Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
    Martin A Pule
    Center for Cell and Gene Therapy, Baylor College of Medicine and The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
    Nat Med 14:1264-70. 2008
    ..Infusion of these genetically modified cells seemed safe and was associated with tumor regression or necrosis in half of the subjects tested. Hence, virus-specific CTLs can be modified to function as tumor-directed effector cells...
  14. ncbi Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma
    Sanjeev A Vasudevan
    Division of Pediatric Surgery, Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    J Pediatr Surg 42:148-52. 2007
    ..The need to detect residual disease and predict prognosis is critical to planning appropriate treatment regimens for these patients. Recently, neuroblastoma-derived secretory protein (NDSP) was identified and cloned from neuroblastoma...